Amneal Pharmaceuticals Q4 Earnings Call Highlights

• 3 Lesser-Known Healthcare Names With Major Upside successful Store

Amneal Pharmaceuticals (NASDAQ:AMRX) reported fourth-quarter and full-year 2025 results and outlined its 2026 outlook, highlighting maturation crossed the business, expanding analyzable merchandise launches, and continued concern successful specialty brands, biosimilars, and GLP-1 manufacturing capacity.

Co-CEO Chirag Patel said 2025 was a “defining year” marked by execution and portfolio expansion. Management reported full-year gross grew 8%, adjusted EBITDA accrued 10%, and adjusted EPS roseate 43%, marking what the institution described arsenic its sixth consecutive twelvemonth of growth.

→ SoundHound’s New Sales Assist Agent Put Voice AI Back successful the Spotlight

• 6 reasons to bargain Teva Pharmaceuticals banal sooner than later

CFO Tassos Konidaris said Amneal exceeded its 2025 fiscal guidance metrics and delivered full-year gross of $3.0 billion. By segment, Affordable Medicines gross grew 4%, Specialty grew 19%, and AvKARE grew 12%. Adjusted gross borderline expanded by 50 ground points to astir 43%, portion adjusted EBITDA grew to $688 cardinal and adjusted EPS roseate to $0.83.

In the 4th quarter, Amneal reported grounds gross of $814 million, up 11% twelvemonth implicit year. Konidaris said Q4 adjusted EBITDA exceeded $175 cardinal (up 13%) and adjusted EPS was $0.21 (up 75%), aided by little involvement disbursal pursuing refinancing completed earlier successful 2025.

→ Microsoft Is Sliding—An Insider Buy and Oversold Signals Are Changing the Setup

Management emphasized advancement connected deleveraging and refinancing. Konidaris said nett leverage declined to 3.5x astatine the extremity of 2025, and the institution generated operating currency travel of $340 cardinal for the year.

Amneal besides refinanced its indebtedness successful 2025 and repriced its Term Loan B successful January, which Konidaris said reduced the company’s weighted mean outgo of indebtedness from 10% successful 2024 to astir 6.8% successful 2026 and extended maturities to 2032. Interest disbursal was $217 cardinal successful 2025 compared with $256 cardinal successful 2024, with absorption expecting a further simplification successful 2026.

→ Diamondback Sees Resilient Demand Despite Cautious Guidance

Leadership positioned Affordable Medicines arsenic a cardinal near-term maturation driver, supported by what it described arsenic a question of analyzable and differentiated launches. Chirag Patel said the segment’s 2025 launches are “multi-year worth drivers,” and the institution expects “meaningful acceleration” successful Affordable Medicines gross maturation successful 2026 and 2027.